Abstract:BackgroundOne of the mechanisms by which tumors evade immune surveillance is through shedding of the major histocompatibility complex (MHC) class I chain-related protein A and B (MICA/B) from their cell surface. MICA/B are ligands for the activating receptor NKG2D on NK and CD8 T cells. This shedding reduces cell surface levels of MICA/B and impairs NKG2D recognition. Shed MICA/B can also mask NKG2D receptor and is thought to induce NKG2D internalization, further compromising immune surveillance by NK cells.MethodsWe isolated human primary NK cells from normal donors and tested the suppressive activity of soluble recombinant MICA in vitro. Utilizing a panel of novel anti-MICA antibodies, we further examined the stimulatory activities of anti-MICA antibodies that reversed the suppressive effects of soluble MICA.ResultsWe show that suppressive effects of soluble MICA (sMICA) on NK cell cytolytic activity was not due to the down-regulation of cell surface NKG2D. In the presence of an α3 domain-specific MICA antibody, which did not obstruct NKG2D binding, sMICA-mediated NK cell suppression was completely reversed. Reversal of NK cell inhibition by sMICA was mediated by immune complex formation that agonized NKG2D signaling. Furthermore, this restorative activity was dependent on antibody Fc effector function as the introduction of Fc mutations to abrogate Fc receptor binding failed to reverse sMICA-mediated NK cell suppression. Furthermore, MICA immune complexes preformed with an α3 domain-specific antibody (containing a wild-type Fc) induced IFN-γ and TNF-α secretion by NK cells in the absence of cancer cells, whereas MICA immune complexes preformed with the Fc effectorless antibody failed to induce IFN-γ and TNF-α secretion. Finally, we demonstrated that MICA immune complexes formed with the α3 domain-specific antibody activates NKG2D on NK cells leading to the release of IFN-γ.ConclusionsOur results demonstrate that an α3 domain-specific MICA antibody can circumvent sMICA-mediated suppression of NK cell cytolytic activity. Moreover, our data suggest that MICA immune complexes formed with α3-specific antibodies can activate NKG2D receptor and restore NK cell function in a Fc-dependent manner. The clinical utility of α3 domain-specific MICA/B antibodies may hold great promise as a new strategy for cancer immunotherapy.

The Opposite Effect of Mmica and Rmica on the Expression of NKG2D and the Influence on NK Cell Receptor Repertoire

Analysis of the expression of MICA on tumor cell lines of different histotypes and their sensitivity to NK cytotoxicity

The clinical and biological significance of MICA in clear cell renal cell carcinoma patients

The Inhibitory Effects of Synthetic Short Peptides, Mimicking MICA and Targeting at NKG2D Receptors, on Function of NK Cells

Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity

Opposing Effects of Interferon-Alpha and Interferon-Gamma on the Expression of Major Histocompatibility Complex Class I Chain-Related A in Tumors.

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillance

MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner

Midkine Upregulates Mica/B Expression in Human Gastric Cancer Cells and Decreases Natural Killer Cell Cytotoxicity

Opposing Effect of IFNγ and IFNα on Expression of NKG2 Receptors: Negative Regulation of IFNγ on NK Cells

Heightened expression of MICA enhances the cytotoxicity of NK cells or CD8 + T cells to human corneal epithelium in vitro

Data from Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity Against Tumors Resistant to Cytotoxic T Cells

The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology

NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells

Interactions of Human Nkg2d with Its Ligands Mica, Micb, and Homologs of the Mouse Rae-1 Protein Family

IFN-γ Regulates the Expression of MICA in Human Corneal Epithelium Through miRNA4448 and NFκB

Expression Pattern of NKG2D on Different Subsets of High Doses IL-2 Activated Human PBMC

[The Negative Regulatory Effect of IFN-gamma on Cognitive Function of Human Natural Killer Cells].

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks